相关实验视频

Updated: Dec 29, 2025

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Published on: June 2, 2022

肠道微生物群通过肠道代谢产物影响小鼠对肥胖的易感性

Yuhang Wen^1,2, Yadan Luo^1,2, Hao Qiu^1,2

¹Laboratory Animal Centre, Southwest Medical University, Luzhou, China.

Frontiers in microbiology

|March 7, 2024

概括

肠道微生物群的差异通过改变脂肪酸和脂等关键代谢物来影响肥胖易感性. 特定的细菌,如Akkermansia,可能在这个过程中发挥作用.

科学领域:

微生物学微生物学
代谢学代谢学代谢学
肥胖问题研究研究

背景情况:

个体对肥胖的易感性各不相同,即使在相同的条件下.
肠道微生物群的组成是影响这种变化的潜在因素.
连接肠道微生物群,代谢物和肥胖风险的确切机制尚未完全理解.

研究的目的:

调查肠道微生物群和肥胖倾向性与耐肥胖小鼠的代谢概况之间的关系.
为了确定与饮食诱导的肥胖相关的特定微生物和代谢变化.

主要方法:

使用高脂肪饮食 (HFD) 建立易患肥胖 (OP) 和耐肥胖 (OR) 的小鼠模型.
通过16S rDNA测序分析便微生物群组成.
使用非向代谢学方法对肠道代谢物进行分析.
相关性和MIMOSA2分析将微生物群和代谢物联系起来.

主要成果:

在HFD后的OP和OR小鼠之间观察到肠道微生物群和代谢概况的显著差异.
肠道微生物群的变化与eicosapentaenoic acid (EPA),docosahexaenoic acid (DHA),基脂肪酸的分支链脂肪酸 (FAHFA) 和脂的水平变化有关.
细菌Akkermansia可能通过胆和L-Valine代谢影响肥胖易感性.
肠道微生物群通过包括histidine代谢,酸代谢和蛋白质消化/吸收在内的途径影响肥胖风险.

结论:

肠道微生物群的组成显著影响了高脂肪饮食的小鼠的代谢概况和肥胖易感性.
特定的微生物物种和代谢途径与肥胖原性饮食的差异反应有关.
准肠道微生物群可能提供一种管理肥胖风险的策略.

关键词:

我们的肠道微生物群.有高脂肪的饮食.容易导致肥胖的人.抗肥胖的方法抗肥胖的方法对肥胖的敏感性.没有目标的代谢学.

更多相关视频

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Anatomy of the Intestines

Anatomy of the Intestines

Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...